Products were recalled because of concerns over salmonella and listeria contamination and undeclared allergens.
The approval of Calquence marks the first and only BTK inhibitor approved for the first-line treatment of MCL in the US.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback